ArticleCureus2026
Endoscopic Band Ligation for Gastric Antral Vascular Ectasia: Report of Two Cases at a Mexican Tertiary Care Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric antral vascular ectasia (GAVE) is an uncommon yet clinically significant cause of chronic upper gastrointestinal bleeding, frequently associated with chronic anemia and recurrent transfusion requirements. Although argon plasma coagulation (APC) remains the most widely used endoscopic therapy, endoscopic band ligation (EBL) is a safe and effective alternative for the treatment of GAVE. We report two female patients with distinct clinical backgrounds and endoscopic presentations of GAVE who underwent EBL at a Mexican tertiary care center where APC was temporarily unavailable. One patient had rheumatoid arthritis and presented with melena and severe anemia, while the other had liver cirrhosis with a history of esophageal varices and presented with chronic anemia and melena. Both patients experienced clinical and hematologic improvement following EBL, with no procedure-related complications. Endoscopic follow-up demonstrated marked regression of GAVE lesions, with one patient requiring a second session because of residual lesions. These findings add to the growing body of evidence supporting EBL as a safe and effective therapeutic option for GAVE across different clinical presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.